Lista de obras - Thomas Fremming Dejgaard

Changes in insulin sensitivity precede changes in body composition during 14 days of step reduction combined with overfeeding in healthy young men.

artículo científico publicado en 2012

Comparative studies of insulin vs glucagon-like peptide-1 receptor agonists in patients initiating injectable therapy

article published in 2016

Continuous glucose monitoring adds information beyond HbA1c in well-controlled diabetes patients with early cardiovascular autonomic neuropathy.

artículo científico publicado en 2017

Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial

artículo científico publicado en 2020

Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes.

artículo científico publicado en 2016

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial

artículo científico publicado en 2015

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study

artículo científico publicado en 2015

Emerging drugs for the treatment of obesity.

artículo científico publicado en 2016

Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy.

artículo científico publicado en 2013

Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes

artículo científico publicado en 2017

Levels of the inflammation marker YKL-40 in young adults exposed to intrauterine hyperglycemia

artículo científico publicado en 2016

Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study

artículo científico publicado en 2016

Liraglutide for treating type 1 diabetes

artículo científico publicado en 2016

Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial

scientific article published on 19 December 2019

Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus

artículo científico publicado en 2016

The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial

artículo científico publicado en 2020

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study

artículo científico publicado en 2015

Lista de obras de Thomas Fremming Dejgaard

Changes in insulin sensitivity precede changes in body composition during 14 days of step reduction combined with overfeeding in healthy young men.

Comparative studies of insulin vs glucagon-like peptide-1 receptor agonists in patients initiating injectable therapy

Continuous glucose monitoring adds information beyond HbA1c in well-controlled diabetes patients with early cardiovascular autonomic neuropathy.

Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial

Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes.

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study

Emerging drugs for the treatment of obesity.

Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy.

Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes

Levels of the inflammation marker YKL-40 in young adults exposed to intrauterine hyperglycemia

Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study

Liraglutide for treating type 1 diabetes

Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial

Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus

The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study